Menu Search
Equities

Opthea Ltd

OPT:ASX

Opthea Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.71
  • Today's Change0.015 / 2.16%
  • Shares traded45.01m
  • 1 Year change+117.13%
  • Beta1.4321
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Opthea Ltd had net income fall 54.53% from a loss of 142.52m to a larger loss of 220.24m despite a 15.00% increase in revenues from 108.41k to 124.67k.
Gross margin100.00%
Net profit margin-176,660.10%
Operating margin-153,990.50%
Return on assets-153.25%
Return on equity--
Return on investment-215.25%
More ▼

Cash flow in USDView more

In 2024, Opthea Ltd increased its cash reserves by 93.38%, or 83.28m. Cash Flow from Financing totalled 243.73m or 195,499.19% of revenues. In addition the company used 161.02m for operations while cash used for investing totalled 33.49k.
Cash flow per share-0.51
Price/Cash flow per share--
Book value per share-0.1027
Tangible book value per share-0.1027
More ▼

Balance sheet in USDView more

Opthea Ltd appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money. Opthea Ltd has considerable financial risk.
Current ratio2.94
Quick ratio--
Total debt/total equity--
Total debt/total capital1.61
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.